secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120673
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront
--------------------------------------------------------------------------------

- Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.
- Upfront payment of $350M; aggregate payments to Royalty Pharma capped at $822.5M.
- Royalty rate subject to adjustments based on future aggregate net sales.
- Syndax retains repurchase right upon change of control; events of default trigger mandatory repurchase at cap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024120673/0000950170-24-120673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024120673/sndx-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer